IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

 Applicant(s)
 : Dudley et al.
 Customer No.
 : 11030

 Serial No.
 : 10/829,618
 Confirmation No.
 : 7286

Filed : 4/20/2004 Group Art Unit : 1627

Examiner : Jean-Louis, Samira

For : Androgen Pharmaceutical Composition and Method for Treating

Depression

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants hereby submit the present Supplemental Information Disclosure
Statement in the application noted above. Enclosed herewith for consideration by the U.S. Patent
and Trademark Office is a listing of a substantive final office action in a related family member.
Applicants note that in the Supplemental IDS submitted on January 12, 2011, an incorrect serial no.
was listed for this entry. Applicants hereby correct the entry with the present submission.

This Information Disclosure Statement is submitted according to the following selected paragraph(s):

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b) (1) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d); (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

a final action or a notice of allowance. Payment for the fee required by is hereby authorized to be charged to Deposit Account No. 02-4377. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under, 37 C.F.R. §1.97(e) prior to either a final action or a no The undersigned hereby states that (check one): each item of information contained in the information disclosure cited in any communication from a foreign patent office in a courapplication not more than three months prior to the filing of the disclosure statement. no item of information contained in the information disclosure is a communication from a foreign patent office in a counterpart for and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information discuss known to any individual designated in 37 C.F.R. § 1.56(c) in months prior to the filing of the information disclosure statement. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all payment of the issue fee. Payment for the fee required by 37 C.F.R. § 1.	osit Account No. 02-4377. being filed under 37 C.F.R. §1.97(e), with a to either a final action or a notice of allowance.
This Information Disclosure Statement is being filed under 37 C.F.R. § statement under, 37 C.F.R. §1.97(e) prior to either a final action or a not The undersigned hereby states that (check one): each item of information contained in the information disclosure cited in any communication from a foreign patent office in a could application not more than three months prior to the filing of the disclosure statement. no item of information contained in the information disclosures a communication from a foreign patent office in a counterpart for and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information discussed known to any individual designated in 37 C.F.R. § 1.56(c) months prior to the filling of the information disclosure statement. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	being filed under 37 C.F.R. §1.97(c), with a to either a final action or a notice of allowance.
statement under, 37 C.F.R. §1.97(e) prior to either a final action or a no The undersigned hereby states that (check one): each item of information contained in the information disclosure cited in any communication from a foreign patent office in a could application not more than three months prior to the filing of the disclosure statement. no item of information contained in the information disclosure s a communication from a foreign patent office in a counterpart for and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information discussed was known to any individual designated in 37 C.F.R. § 1.56(c) it months prior to the filling of the information disclosure statement. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	to either a final action or a notice of allowance.
The undersigned hereby states that (check one): each item of information contained in the information disclosure cited in any communication from a foreign patent office in a could application not more than three months prior to the filing of the disclosure statement. no item of information contained in the information disclosure is a communication from a foreign patent office in a counterpart for and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information discuss was known to any individual designated in 37 C.F.R. § 1.56(c) is months prior to the filing of the information disclosure statement. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	
each item of information contained in the information disclosure cited in any communication from a foreign patent office in a courapplication not more than three months prior to the filing of the disclosure statement. no item of information contained in the information disclosure s a communication from a foreign patent office in a counterpart for and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information discuss was known to any individual designated in 37 C.F.R. § 1.56(c) months prior to the filing of the information disclosure statement. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	one):
cited in any communication from a foreign patent office in a cou application not more than three months prior to the filing of the disclosure statement. no item of information contained in the information disclosure s a communication from a foreign patent office in a counterpart for and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information discuss known to any individual designated in 37 C.F.R. § 1.56(c) months prior to the filing of the information disclosure statement. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	
application not more than three months prior to the filing of the disclosure statement. no item of information contained in the information disclosure s a communication from a foreign patent office in a counterpart for and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information discuss known to any individual designated in 37 C.F.R. § 1.56(c) 1 months prior to the filing of the information disclosure statement. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	in the information disclosure statement was first
disclosure statement. no item of information contained in the information disclosure s a communication from a foreign patent office in a counterpart for and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information discuss known to any individual designated in 37 C.F.R. § 1.56(c) 1 months prior to the filing of the information disclosure statement. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	a foreign patent office in a counterpart foreign
no item of information contained in the information disclosure s a communication from a foreign patent office in a counterpart for and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information discuss known to any individual designated in 37 C.F.R. § 1.56(c) 1 months prior to the filing of the information disclosure statement. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	onths prior to the filing of the information
a communication from a foreign patent office in a counterpart fe and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information disters was known to any individual designated in 37 C.F.R. § 1.56(c) I months prior to the filing of the information disclosure statemen. This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	
and, to the knowledge of the person signing the certification after inquiry, no item of information contained in the information dist was known to any individual designated in 37 C.F.R. § 1.56(c) I months prior to the filing of the information disclosure statemen This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	n the information disclosure statement was cited in
inquiry, no item of information contained in the information diswas known to any individual designated in 37 C.F.R. § 1.56(c) months prior to the filing of the information disclosure statemen This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	atent office in a counterpart foreign application,
was known to any individual designated in 37 C.F.R. § 1.56(c) a months prior to the filing of the information disclosure statemen This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	n signing the certification after making reasonable
months prior to the filing of the information disclosure statemen This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	ntained in the information disclosure statement
This Information Disclosure Statement is being filed under 37 C.F.R. § statement under 37 C.F.R. § 1.97(e), after a final action or a notice of all	gnated in 37 C.F.R. § 1.56(c) more than three
statement under 37 C.F.R. §1.97(e), after a final action or a notice of all	formation disclosure statement.
statement under 37 C.F.R. §1.97(e), after a final action or a notice of all	being filed under 37 C.F.R. 81.97(d), with a
	•
authorized to be charged to Deposit Account No. 02-4377. The undersi	• • • • • • • • • • • • • • • • • • • •
petitions that this Information Disclosure Statement be considered prior	• •
patent. The undersigned hereby states that (check one):	•
each item of information contained in the information disclosure	· ·
cited in any communication from a foreign patent office in a cou	
,	
application not more than three months prior to the filing of the	a foreign patent office in a counterpart foreign
application not more than three months prior to the filing of the disclosure statement.	a foreign patent office in a counterpart foreign
disclosure statement.	a foreign patent office in a counterpart foreign onths prior to the filling of the information
disclosure statement. no item of information contained in the information disclosure s	a foreign patent office in a counterpart foreign onths prior to the filling of the information n the information disclosure statement was cited in
disclosure statement.	a foreign patent office in a counterpart foreign onths prior to the filing of the information In the information disclosure statement was cited in atent office in a counterpart foreign application,

was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the information disclosure statement.

	The references listed on the accompanying PTO-1449 were either cited by the Examiner of	г
	previously submitted in parent application U.S. Serial No, filed	_,
	Pursuant to 37 C.F.R. § 1.98(d), the references are not required if the earlier application is	
	identified and relied upon for an effective filing date under 35 U.S.C. \S 120 and therefore	
	are not enclosed herewith.	
	Related Application Disclosure	
	Applicants would like to bring to the attention of the Examiner the following related paten	t
	applications, which are also listed on the accompanying PTO-1449:	
	Disclosure of Office Actions and Responses in Related Applications	
\boxtimes	Applicants would like to bring to the attention of the Examiner the following Office Action	ns
	issued in related patent applications and Responses to Office Actions filed in such	
	applications, which are also listed on the accompanying PTO-1449:	

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

12-30-2010 Final Rejection

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

12/543,541

Applicants believe no fee is due in connection with this submission. However, if any fee is due, or if any overpayment has been made, the Commissioner is authorized to charge any such fee or credit any overpayment to our Deposit Account No. 02-4377.

Respectfully submitted,

Date: January 26, 2011

Sardia Lee

Sandra S. Lee Patent Office Reg. No. 51,932

Daniel Hulseberg Patent Office Reg. No. 36,554

Baker Botts L.L.P. CUSTOMER NO. 11030

30 Rockefeller Plaza 44th Floor New York, NY 10012-4498 Attorney for Applicant(s) 212-408-2500